Your AI-Trained Oncology Knowledge Connection!

ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma : Episode 17

Opinion

Video

April 19, 2024

Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.

EP: 1.First-Line Treatments for Advanced Clear Cell RCC

EP: 2.Long-Term Follow-Up from CheckMate 214 in Advanced RCC

EP: 3.CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

EP: 4.Recent Subgroup Analyses from the CLEAR study in Advanced RCC

EP: 5.LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

EP: 6.Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

EP: 7.CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

EP: 8.Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

EP: 9.LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

EP: 10.Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

EP: 11.CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

EP: 12.Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

EP: 13.Clinical Insights on Belzutifan in Advanced RCC

EP: 14.Overview of Non–Clear Cell RCC

EP: 15.TKI Monotherapy Data in Non–Clear Cell RCC

EP: 16.KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

Now Viewing

EP: 17.Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

EP: 18.Future Perspectives and Unmet Needs in Renal Cell Carcinoma

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity

Latest Conference Coverage

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

EP: 1.First-Line Treatments for Advanced Clear Cell RCC

EP: 2.Long-Term Follow-Up from CheckMate 214 in Advanced RCC

EP: 3.CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

EP: 4.Recent Subgroup Analyses from the CLEAR study in Advanced RCC

EP: 5.LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

EP: 6.Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

EP: 7.CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

EP: 8.Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

EP: 9.LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

EP: 10.Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

EP: 11.CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

EP: 12.Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

EP: 13.Clinical Insights on Belzutifan in Advanced RCC

EP: 14.Overview of Non–Clear Cell RCC

EP: 15.TKI Monotherapy Data in Non–Clear Cell RCC

EP: 16.KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

EP: 17.Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

EP: 18.Future Perspectives and Unmet Needs in Renal Cell Carcinoma

Newsletter

Latest CME

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Latest Conference Coverage